Dermatitis News and Research

Latest Dermatitis News and Research

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Signum Dermalogix, Inc. announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the company a Small Business Innovation Research Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.

15 Nov 2013

Index predicts asthma in high-risk preschool children

Researchers have shown that the modified Asthma Predictive Index has high predictive value for future asthma development, when applied in the first 3 years of life.

12 Nov 2013

Gene mutations responsible for persistent AD in African American children

Two specific genetic variations in people of African descent are responsible for persistent atopic dermatitis (AD), an itchy, inflammatory form of the skin disorder eczema. A new report by researchers in the Perelman School of Medicine at the University of Pennsylvania found that loss-of-function mutations to Filaggrin-2 (FLG2), a gene that creates a protein responsible for retaining moisture and protecting the skin from environmental irritants, were associated with atopic dermatitis in African American children.

12 Nov 2013

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Polyphor Ltd, a privately held pharmaceutical company, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.

4 Nov 2013

New finding could help lead to better treatments for eczema

For the millions of people suffering from the intensely red, horribly itchy skin condition known as eczema, the only thing more maddening than their disease is the lack of understanding of what causes it, or makes it flare up from time to time.

31 Oct 2013

Dermatologists provide list of specific treatments, procedures not required for medical care

The American Academy of Dermatology today released its list of specific treatments and procedures related to skin health and care that are not always necessary.

29 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

New discovery may lead to effective treatments for chronic itching

Anyone who has suffered through sleepless nights due to uncontrollable itching knows that not all itching is the same. New research at Washington University School of Medicine in St. Louis explains why.

16 Oct 2013

Asthma infection risk ‘goes beyond the airways’

Researchers from the USA have found that asthma may be associated with an increased risk for infections outside of the respiratory tract.

9 Oct 2013

New picture of interaction between nervous & immune systems could lead to novel therapies

A new picture of how the nervous system interacts with the immune system to cause the itch and inflammation associated with eczema, a chronic skin disease, could lead to new therapies for the condition, according to University of California, Berkeley, scientists.

4 Oct 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

Proton therapy reduces treatment side effects among head and neck cancer patients

The precise targeting and limited dosing of radiation via proton therapy is proving to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients, according to a new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania.

25 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.

27 Aug 2013

Study: Structural defect in skin cells can contribute to allergy development

In a new study published in Nature Genetics, Northwestern Medicine and Tel Aviv University scientists have found that a structural defect in skin cells can contribute to allergy development, including skin and food allergies, traditionally thought primarily to be a dysfunction of the immune system.

27 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Dermatitis News and Research

Latest Dermatitis News and Research

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Index predicts asthma in high-risk preschool children

Gene mutations responsible for persistent AD in African American children

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

New finding could help lead to better treatments for eczema

Dermatologists provide list of specific treatments, procedures not required for medical care

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

New discovery may lead to effective treatments for chronic itching

Asthma infection risk ‘goes beyond the airways’

New picture of interaction between nervous & immune systems could lead to novel therapies

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Proton therapy reduces treatment side effects among head and neck cancer patients

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

FDA approves Galderma's Mirvaso topical gel for facial erythema of rosacea

Study: Structural defect in skin cells can contribute to allergy development

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Dermatitis News and Research

Latest Dermatitis News and Research

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in